This hypothesis was based on three observations reported in a previous study: (1) metformin is associated with a low risk of IBD in diabetes mellitus patients [28], (2) rectal insulin instillation reduces colon inflammation through the insulin receptor [12], and (3) the gut microbiota can influence the effect of hypoglycemic agents [27, 48]. This evidence concerns the gene INS and inflammatory bowel disease.